Tuesday, 31 Mar 2020

You are here

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

This single center study included 100 inpatients (115 episodes of arthritis) treated for crystal-associated arthritis with anakinra between 2014 and 2017. Most (82%) were male, with an average age of 60 years and had many expected comorbidities included renal disease (45%) and organ transplantation (14%). Nearly 25-30% had perioperative arthritis or concurrent infection.

Responses to anakinra yielded a partial or complete response within 4 days in 75% of patients with 75% of these responding within one day of anakinra administration. Anakinra was otherwise well tolerated.

Anakinra appears to be an effective treatment option for complex, inpatients (e.g., perioperative or immunosuppressed patients) who are refractory to or unable to receive usual therapies for acute crystal-associated arthritis in the hospital.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.